Targeted therapeutic options and future perspectives for HER2-positive breast cancer von Wang, Jiani, Xu, Binghe

Volltext

Breast cancer: an up‐to‐date review and future perspectives von Hong, Ruoxi, Xu, Binghe

Volltext

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation von Robson, Mark, Im, Seock-Ah, Senkus, Elżbieta, Xu, Binghe, Domchek, Susan M, Masuda, Norikazu, Delaloge, Suzette, Li, Wei, Tung, Nadine, Armstrong, Anne, Wu, Wenting, Goessl, Carsten, Runswick, Sarah, Conte, Pierfranco

Volltext

MicroRNA-21 identified as predictor of cancer outcome: a meta-analysis von Zhu, Wenjie, Xu, Binghe

Volltext

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma von Huang, Jing, Xu, Binghe, Mo, Hongnan, Zhang, Weilong, Chen, Xuelian, Wu, Dawei, Qu, Dong, Wang, Xingyuan, Lan, Bo, Yang, Beibei, Wang, Pei, Zhang, Hongtu, Yang, Qing, Jiao, Yuchen

Volltext

Breast cancer: Epidemiology, risk factors and screening von Xu, Hangcheng, Xu, Binghe

Volltext

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer von Modi, Shanu, Jacot, William, Yamashita, Toshinari, Sohn, Joohyuk, Vidal, Maria, Tokunaga, Eriko, Tsurutani, Junji, Ueno, Naoto T., Prat, Aleix, Chae, Yee Soo, Lee, Keun Seok, Niikura, Naoki, Park, Yeon Hee, Xu, Binghe, Wang, Xiaojia, Gil-Gil, Miguel, Li, Wei, Pierga, Jean-Yves, Im, Seock-Ah, Moore, Halle C.F., Rugo, Hope S., Yerushalmi, Rinat, Zagouri, Flora, Gombos, Andrea, Kim, Sung-Bae, Liu, Qiang, Luo, Ting, Saura, Cristina, Schmid, Peter, Sun, Tao, Gambhire, Dhiraj, Yung, Lotus, Wang, Yibin, Singh, Jasmeet, Vitazka, Patrik, Meinhardt, Gerold, Harbeck, Nadia, Cameron, David A.

Volltext

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR +/HER2 --) advanced breast cancer: a meta-analysis and... von Zhu, Wenjie, Xu, Binghe

Volltext

Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis von Han, Yiqun, Wang, Jiayu, Xu, Binghe

Volltext

Preface to Special Issue: Cancer epidemiology, risk factors and screening von Xu, Binghe, Xu, Hangcheng

Volltext

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study von Han, Yiqun, Wu, Yun, Xu, Hangcheng, Wang, Jiayu, Xu, Binghe

Volltext

Fragmentation patterns of cell-free DNA and somatic mutations in the urine of metastatic breast cancer patients von Lin, Shaoyan, Wang, Shusen, Xu, Binghe

Volltext

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial von Xu, Binghe, Zhang, Qingyuan, Zhang, Pin, Hu, Xichun, Li, Wei, Tong, Zhongsheng, Sun, Tao, Teng, Yuee, Wu, Xinhong, Ouyang, Quchang, Yan, Xi, Cheng, Jing, Liu, Qiang, Feng, Jifeng, Wang, Xiaojia, Yin, Yongmei, Shi, Yanxia, Pan, Yueyin, Wang, Yongsheng, Xie, Weimin, Yan, Min, Liu, Yunjiang, Yan, Ping, Wu, Fei, Zhu, Xiaoyu, Zou, Jianjun

Volltext

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 von Coates, A.S., Winer, E.P., Goldhirsch, A., Gelber, R.D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, Fabrice, Baselga, José, Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Coates, Alan S., Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Di Leo, Angelo, Ejlertsen, Bent, Forbes, John F., Galimberti, Viviana, Gelber, Richard D., Gnant, Michael, Goldhirsch, Aron, Goodwin, Pamela, Harbeck, Nadia, Hayes, Daniel F., Huober, Jens, Hudis, Clifford A., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Morrow, Monica, Orecchia, Roberto, Kent Osborne, C., Partridge, Ann H., de la Peña, Lorena, Piccart-Gebhart, Martine J., Pritchard, Kathleen I., Rutgers, Emiel J.T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, von Minckwitz, Gunter, Watanabe, Toru, Whelan, Timothy, Winer, Eric P., Xu, Binghe

Volltext

Progress in systemic therapy for triple-negative breast cancer von Mo, Hongnan, Xu, Binghe

Volltext

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer von Hu, Xichun, Zhang, Jian, Xu, Binghe, Jiang, Zefei, Ragaz, Joseph, Tong, Zhongsheng, Zhang, Qingyuan, Wang, Xiaojia, Feng, Jifeng, Pang, Danmei, Fan, Minhao, Li, Jin, Wang, Biyun, Wang, Zhonghua, Zhang, Qunling, Sun, Si, Liao, Chunmei

Volltext

Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study von Zhu, Wenjie, Xu, Binghe

Volltext

Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis von Han, Yiqun, Wang, Jiayu, Wang, Zijing, Xu, Binghe

Volltext

Enriched CD44+ /CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC) von Ma, Fei, Li, Huihui, Wang, Haijuan, Shi, Xiuqing, Fan, Ying, Ding, Xiaoyan, Lin, Chen, Zhan, Qimin, Qian, Haili, Xu, Binghe

Volltext

An immunogenic cell death-related signature for prediction of prognosis and response to immunotherapy in breast cancer von Li, Cong, Guo, Fengzhu, Zhai, Jingtong, Liu, Xiaohan, Li, Zhijun, Xu, Binghe

Volltext